1. Delemarre-van de Waal HA. Environ Health Perspect. 1993;101(Suppl 2):39–44
2. Sogroya® Summary of Product Characteristics.
3. Johannsson G, Gordon MB, Rasmussen MH, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):1–19.
4. Johannsson G, Feldt-Rasmussen U, Håkonsson IH, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178(5):491–499.
5. Yuen KCJ, Llahana S, Miller BS. Adult growth hormone deficiency: clinical advances and approaches to improve adherence. Expert Rev Endocrinol Metab. 2019;14(6):419–436.